Literature DB >> 14229761

CURRENT STATUS OF MEASLES AND ORAL POLIOVIRUS VACCINES.

D R MACLEOD.   

Abstract

Live attenuated measles vaccine, accompanied by a dose of gamma globulin to reduce systemic reactions, has given a high degree of protection, probably long lasting. Further attenuated vaccine gives promise of achieving the same result without the use of gamma globulin. Inactivated vaccine has not been shown to give durable immunity, but a schedule of killed vaccine followed by live vaccine has provided protection with minimal reactions. Inactivated vaccine can probably be combined with other antigens.Sabin oral poliovirus vaccines of all three types have been highly effective in preventing paralytic illness and reducing the spread of virulent strains. Because of the rare occurrence, chiefly in adults, of paralytic cases considered to be probably vaccine-associated, though no proof was possible, it has been recommended in Canada that initial immunization with Salk vaccine be continued and that all infants and children should subsequently receive trivalent Sabin vaccine.

Entities:  

Keywords:  CANADA; GAMMA GLOBULIN; MEASLES VACCINE; POLIOVIRUS VACCINE, ORAL

Mesh:

Substances:

Year:  1964        PMID: 14229761      PMCID: PMC1928369     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


  37 in total

1.  An outbreak of poliomyelitis in Israel in 1961 and the use of attenuated type 1 vaccine in its control.

Authors:  J YOFE; N GOLDBLUM; E EYLAN; J L MELNICK
Journal:  Am J Hyg       Date:  1962-11

2.  Response of 3-months-old infants to 3 doses of trivalent oral poliomyelitis vaccine.

Authors:  F T PERKINS; R YETTS; W GAISFORD
Journal:  Br Med J       Date:  1963-06-15

3.  Measles virus. Historical review, isolation, and behavior in various systems.

Authors:  J F ENDERS
Journal:  Am J Dis Child       Date:  1962-03

4.  Serologic response of children to in-activated measles vaccine.

Authors:  C H CARTER; T J CONWAY; D CORNFELD; D G IEZZONI; C H KEMPE; C MOSCOVICI; L W RAUH; A J VIGNEC; J WARREN
Journal:  JAMA       Date:  1962-03-17       Impact factor: 56.272

5.  Preliminary tests of a highly attenuated measles vaccine.

Authors:  A J SCHWARZ
Journal:  Am J Dis Child       Date:  1962-03

6.  Use of Edmonston attenuated measles strain. A summary of three years' experience.

Authors:  S L KATZ; J F ENDERS; A HOLLOWAY
Journal:  Am J Dis Child       Date:  1962-03

7.  Status of field trials with an orally administered, live attenuated poliovirus vaccine.

Authors:  A B SABIN
Journal:  J Am Med Assoc       Date:  1959-10-17

8.  Studies on an attenuated measles-virus vaccine. VIII. General summary and evaluation of the results of vaccine.

Authors:  S L KATZ; C H KEMPE; F L BLACK; M L LEPOW; S KRUGMAN; R J HAGGERTY; J F ENDERS
Journal:  N Engl J Med       Date:  1960-07-28       Impact factor: 91.245

9.  Inactivated measles virus vaccine. II. Prevention of natural and experimental measles with the vaccine.

Authors:  H A FELDMAN; A NOVACK; J WARREN
Journal:  JAMA       Date:  1962-02-10       Impact factor: 56.272

10.  IMMUNIZATION WITH LIVE MEASLES VIRUS VACCINE.

Authors:  H R BRODIE
Journal:  Can Med Assoc J       Date:  1963-09-14       Impact factor: 8.262

View more
  1 in total

1.  An Emerging Duck Egg-Reducing Syndrome Caused by a Novel Picornavirus Containing Seven Putative 2A Peptides.

Authors:  Xin Su; Dun Shuo; Yanqiu Luo; Xue Pan; Dawei Yan; Xuesong Li; Weishan Lin; Dongming Huang; Jianmei Yang; Chunxiu Yuan; Qinfang Liu; Qiaoyang Teng; Zejun Li
Journal:  Viruses       Date:  2022-04-29       Impact factor: 5.818

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.